Jenesis Biosciences LLC is exploring novel technologies in molecular targets for treatment of diabetes complications, biomarkers for risk of disease and response to treatments in diabetes, and beta cell markers of growth and maturation. The company has a pipeline of platform technologies that will identify and develop targets for treatment of diabetes and complications. Several key areas of markers are currently being developed and validated in collaboration with Joslin: * Treatment of complications, * Molecular Factors in Exercise-mediated Benefit in Diabetes, * Beta cell development and maturation.
